Cannabis contains more than 100 phytocannabinoids. Most of these remain poorly characterized, particularly in neurons. We tested a panel of five phytocannabinoids-cannabichromene (CBC), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), and Δ9-tetrahydrocannabivarin (THCV) in two neuronal models, autaptic hippocampal neurons and dorsal root ganglion (DRG) neurons. Autaptic neurons expressed a form of CB1-dependent retrograde plasticity while DRGs expressed a variety of transient receptor potential (TRP) channels. CBC, CBDA, and CBDVA had little or no effect on neuronal cannabinoid signaling. CBDV and THCV differentially inhibited cannabinoid signaling. THCV inhibited CB1 receptors presynaptically while CBDV acted post-synaptically, perhaps by inhibiting 2-AG production. None of the compounds elicited a consistent DRG response. In summary, we find that two of five 'minor' phytocannabinoids tested antagonized CB1-based signaling in a neuronal model, but with very different mechanisms. Our findings highlight the diversity of potential actions of phytocannabinoids and the importance of fully evaluating these compounds in neuronal models.

Department of Molecular Pharmacology Institute of Molecular Genetics of the Czech Academy of Sciences Videnska 1083 14220 Prague Czech Republic

Gill Center for Molecular Bioscience Program in Neuroscience Department of Psychological and Brain Sciences Indiana University Bloomington IN 47405 USA

Zobrazit více v PubMed

Elsohly M.A., Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78:539–548. doi: 10.1016/j.lfs.2005.09.011. PubMed DOI

Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964;86:1646–1647. doi: 10.1021/ja01062a046. DOI

Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002;54:161–202. doi: 10.1124/pr.54.2.161. PubMed DOI

Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564. doi: 10.1038/346561a0. PubMed DOI

Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65. doi: 10.1038/365061a0. PubMed DOI

Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003;4:873–884. doi: 10.1038/nrn1247. PubMed DOI

Adams R., Hunt M., Clark J.H. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J. Am. Chem. Soc. 1940;62:4. doi: 10.1021/ja01858a058. DOI

Billakota S., Devinsky O., Marsh E. Cannabinoid therapy in epilepsy. Curr. Opin. Neurol. 2019;32:220–226. doi: 10.1097/WCO.0000000000000660. PubMed DOI

Luo X., Reiter M.A., d’Espaux L., Wong J., Denby C.M., Lechner A., Zhang Y., Grzybowski A.T., Harth S., Lin W., et al. Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. Nature. 2019;567:123–126. doi: 10.1038/s41586-019-0978-9. PubMed DOI

Russo E.B. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 2011;163:1344–1364. doi: 10.1111/j.1476-5381.2011.01238.x. PubMed DOI PMC

Mechoulam R., Parker L.A., Gallily R. Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol. 2002;42:11S–19S. doi: 10.1002/j.1552-4604.2002.tb05998.x. PubMed DOI

Laprairie R.B., Bagher A.M., Kelly M.E., Denovan-Wright E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 2015;172:4790–4805. doi: 10.1111/bph.13250. PubMed DOI PMC

Straiker A., Dvorakova M., Zimmowitch A., Mackie K. Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Mol. Pharmacol. 2018;94:743–748. doi: 10.1124/mol.118.111864. PubMed DOI PMC

Murataeva N., Straiker A., Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br. J. Pharmacol. 2014;171:1379–1391. doi: 10.1111/bph.12411. PubMed DOI PMC

Muller C., Morales P., Reggio P.H. Cannabinoid Ligands Targeting TRP Channels. Front. Mol. Neurosci. 2018;11:487. doi: 10.3389/fnmol.2018.00487. PubMed DOI PMC

Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) Br. J. Pharmacol. 2000;129:227–230. doi: 10.1038/sj.bjp.0703050. PubMed DOI PMC

Straiker A., Mackie K. Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J. Physiol. 2005;569:501–517. doi: 10.1113/jphysiol.2005.091918. PubMed DOI PMC

Straiker A., Mackie K. Metabotropic suppression of excitation in murine autaptic hippocampal neurons. J. Physiol. 2007;578:773–785. doi: 10.1113/jphysiol.2006.117499. PubMed DOI PMC

Kellogg R., Mackie K., Straiker A. Cannabinoid CB1 receptor-dependent long-term depression in autaptic excitatory neurons. J. Neurophysiol. 2009;102:1160–1171. doi: 10.1152/jn.00266.2009. PubMed DOI PMC

Bekkers J.M., Stevens C.F. Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture. Proc. Natl. Acad. Sci. USA. 1991;88:7834–7838. doi: 10.1073/pnas.88.17.7834. PubMed DOI PMC

Furshpan E.J., MacLeish P.R., O’Lague P.H., Potter D.D. Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: Evidence for cholinergic, adrenergic, and dual-function neurons. Proc. Natl. Acad. Sci. USA. 1976;73:4225–4229. doi: 10.1073/pnas.73.11.4225. PubMed DOI PMC

Levison S.W., McCarthy K.D. Characterization and partial purification of AIM: A plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors. J. Neurochem. 1991;57:782–794. doi: 10.1111/j.1471-4159.1991.tb08220.x. PubMed DOI

Harada K., Ito M., Wang X., Tanaka M., Wongso D., Konno A., Hirai H., Hirase H., Tsuboi T., Kitaguchi T. Red fluorescent protein-based cAMP indicator applicable to optogenetics and in vivo imaging. Sci. Rep. 2017;7:7351. doi: 10.1038/s41598-017-07820-6. PubMed DOI PMC

Thomas L.S., Gehrig J. ImageJ/Fiji ROI 1-click tools for rapid manual image annotations and measurements. MicroPubl. Biol. :2020. doi: 10.17912/micropub.biology.000215. PubMed DOI PMC

Sleigh J.N., Weir G.A., Schiavo G. A simple, step-by-step dissection protocol for the rapid isolation of mouse dorsal root ganglia. BMC Res. Notes. 2016;9:82. doi: 10.1186/s13104-016-1915-8. PubMed DOI PMC

Hatoum N.S., Davis W.M., Elsohly M.A., Turner C.E. Cannabichromene and delta 9-tetrahydrocannabinol: Interactions relative to lethality, hypothermia and hexobarbital hypnosis. Gen. Pharmacol. 1981;12:357–362. doi: 10.1016/0306-3623(81)90090-2. PubMed DOI

Davis W.M., Hatoum N.S. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen. Pharmacol. 1983;14:247–252. doi: 10.1016/0306-3623(83)90004-6. PubMed DOI

Wirth P.W., Watson E.S., ElSohly M., Turner C.E., Murphy J.C. Anti-inflammatory properties of cannabichromene. Life Sci. 1980;26:1991–1995. doi: 10.1016/0024-3205(80)90631-1. PubMed DOI

Udoh M., Santiago M., Devenish S., McGregor I.S., Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br. J. Pharmacol. 2019;176:4537–4547. doi: 10.1111/bph.14815. PubMed DOI PMC

De Petrocellis L., Ligresti A., Moriello A.S., Allara M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011;163:1479–1494. doi: 10.1111/j.1476-5381.2010.01166.x. PubMed DOI PMC

Maione S., Piscitelli F., Gatta L., Vita D., De Petrocellis L., Palazzo E., de Novellis V., Di Marzo V. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br. J. Pharmacol. 2011;162:584–596. doi: 10.1111/j.1476-5381.2010.01063.x. PubMed DOI PMC

DeLong G.T., Wolf C.E., Poklis A., Lichtman A.H. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend. 2010;112:126–133. doi: 10.1016/j.drugalcdep.2010.05.019. PubMed DOI PMC

Shinjyo N., Di Marzo V. The effect of cannabichromene on adult neural stem/progenitor cells. Neurochem. Int. 2013;63:432–437. doi: 10.1016/j.neuint.2013.08.002. PubMed DOI

Mitjavila J., Yin D., Kulkarni P.M., Zanato C., Thakur G.A., Ross R., Greig I., Mackie K., Straiker A. Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacol. Res. 2018;129:475–481. doi: 10.1016/j.phrs.2017.11.019. PubMed DOI PMC

Straiker A., Mitjavila J., Yin D., Gibson A., Mackie K. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model. Pharmacol. Res. 2015;99:370–376. doi: 10.1016/j.phrs.2015.07.017. PubMed DOI PMC

Taura F., Morimoto S., Shoyama Y. Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.. Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid. J. Biol. Chem. 1996;271:17411–17416. doi: 10.1074/jbc.271.29.17411. PubMed DOI

Guy G., Wright S., Brodie J., Woolley-Roberts M., Maldonado R., Parolaro D., Luongo L. Use of Cannabidiolic Acid in the Treatment of Autism Spectrum Disorder and Associated Disorders. [(accessed on 15 July 2021)];2019 Available online: https://patentscope.wipo.int/search/en/detail.jsf?docId=US241444657&docAn=16092560.

Bolognini D., Costa B., Maione S., Comelli F., Marini P., Di Marzo V., Parolaro D., Ross R.A., Gauson L.A., Cascio M.G., et al. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br. J. Pharmacol. 2010;160:677–687. doi: 10.1111/j.1476-5381.2010.00756.x. PubMed DOI PMC

Kleinhenz M.D., Magnin G., Lin Z., Griffin J., Kleinhenz K.E., Montgomery S., Curtis A., Martin M., Coetzee J.F. Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa) Sci. Rep. 2020;10:12753–12763. doi: 10.1038/s41598-020-69768-4. PubMed DOI PMC

Anderson L.L., Low I.K., Banister S.D., McGregor I.S., Arnold J.C. Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. J. Nat. Prod. 2019;82:3047–3055. doi: 10.1021/acs.jnatprod.9b00600. PubMed DOI

Merkus F.W. Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature. 1971;232:579–580. doi: 10.1038/232579a0. PubMed DOI

Thomas A., Stevenson L.A., Wease K.N., Price M.R., Baillie G., Ross R.A., Pertwee R.G. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br. J. Pharmacol. 2005;146:917–926. doi: 10.1038/sj.bjp.0706414. PubMed DOI PMC

Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008;153:199–215. doi: 10.1038/sj.bjp.0707442. PubMed DOI PMC

Hill A.J., Weston S.E., Jones N.A., Smith I., Bevan S.A., Williamson E.M., Stephens G.J., Williams C.M., Whalley B.J. Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia. 2010;51:1522–1532. doi: 10.1111/j.1528-1167.2010.02523.x. PubMed DOI

Straiker A.J., Borden C.R., Sullivan J.M. G-Protein alpha Subunit Isoforms Couple Differentially to Receptors that Mediate Presynaptic Inhibition at Rat Hippocampal Synapses. J. Neurosci. 2002;22:2460–2468. doi: 10.1523/JNEUROSCI.22-07-02460.2002. PubMed DOI PMC

Howlett A.C. Cannabinoid inhibition of adenylate cyclase: Relative activity of constituents and metabolites of marihuana. Neuropharmacology. 1987;26:507–512. doi: 10.1016/0028-3908(87)90035-9. PubMed DOI

Howlett A.C. Pharmacology of cannabinoid receptors. Annu Rev. Pharmacol. Toxicol. 1995;35:607–634. doi: 10.1146/annurev.pa.35.040195.003135. PubMed DOI

Vollner L., Bieniek D., Korte F. Hashish. XX. Cannabidivarin, a new hashish constituent. Tetrahedron Lett. 1969;3:145–147. doi: 10.1016/S0040-4039(01)87494-3. PubMed DOI

Hill A.J., Mercier M.S., Hill T.D., Glyn S.E., Jones N.A., Yamasaki Y., Futamura T., Duncan M., Stott C.G., Stephens G.J., et al. Cannabidivarin is anticonvulsant in mouse and rat. Br. J. Pharmacol. 2012;167:1629–1642. doi: 10.1111/j.1476-5381.2012.02207.x. PubMed DOI PMC

Hill T.D., Cascio M.G., Romano B., Duncan M., Pertwee R.G., Williams C.M., Whalley B.J., Hill A.J. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br. J. Pharmacol. 2013;170:679–692. doi: 10.1111/bph.12321. PubMed DOI PMC

Iannotti F.A., Hill C.L., Leo A., Alhusaini A., Soubrane C., Mazzarella E., Russo E., Whalley B.J., Di Marzo V., Stephens G.J. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability. ACS Chem. Neurosci. 2014;5:1131–1141. doi: 10.1021/cn5000524. PubMed DOI

Amada N., Yamasaki Y., Williams C.M., Whalley B.J. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ. 2013;1:e214. doi: 10.7717/peerj.214. PubMed DOI PMC

Huizenga M.N., Sepulveda-Rodriguez A., Forcelli P.A. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 2019;148:189–198. doi: 10.1016/j.neuropharm.2019.01.002. PubMed DOI PMC

Zamberletti E., Gabaglio M., Piscitelli F., Brodie J.S., Woolley-Roberts M., Barbiero I., Tramarin M., Binelli G., Landsberger N., Kilstrup-Nielsen C., et al. Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. J. Psychopharmacol. 2019;33:894–907. doi: 10.1177/0269881119844184. PubMed DOI

Schroeder J.E., McCleskey E.W. Inhibition of Ca2+ currents by a mu-opioid in a defined subset of rat sensory neurons. J. Neurosci. 1993;13:867–873. doi: 10.1523/JNEUROSCI.13-02-00867.1993. PubMed DOI PMC

Wangzhou A., McIlvried L.A., Paige C., Barragan-Iglesias P., Shiers S., Ahmad A., Guzman C.A., Dussor G., Ray P.R., Gereau R.W., et al. Pharmacological target-focused transcriptomic analysis of native vs cultured human and mouse dorsal root ganglia. Pain. 2020;161:1497–1517. doi: 10.1097/j.pain.0000000000001866. PubMed DOI PMC

Devinsky O., Patel A.D., Thiele E.A., Wong M.H., Appleton R., Harden C.L., Greenwood S., Morrison G., Sommerville K., On behalf of the GWPCARE1 Part A Study Group Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:1204–1211. doi: 10.1212/WNL.0000000000005254. PubMed DOI PMC

Anderson L.L., Etchart M.G., Bahceci D., Golembiewski T.A., Arnold J.C. Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. Sci. Rep. 2021;11:14948. doi: 10.1038/s41598-021-94212-6. PubMed DOI PMC

Doohan P.T., Oldfield L.D., Arnold J.C., Anderson L.L. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: A Full-Spectrum Characterization. AAPS J. 2021;23:91. doi: 10.1208/s12248-021-00616-7. PubMed DOI

Riedel G., Fadda P., McKillop-Smith S., Pertwee R.G., Platt B., Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br. J. Pharmacol. 2009;156:1154–1166. doi: 10.1111/j.1476-5381.2008.00107.x. PubMed DOI PMC

Tudge L., Williams C., Cowen P.J., McCabe C. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int. J. Neuropsychopharmacol. 2015;18:1–9. doi: 10.1093/ijnp/pyu094. PubMed DOI PMC

McPartland J.M., Duncan M., Di Marzo V., Pertwee R.G. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol. 2015;172:737–753. doi: 10.1111/bph.12944. PubMed DOI PMC

Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 1998;353:23–31. doi: 10.1016/S0014-2999(98)00392-6. PubMed DOI

Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: Evidence for new players. AAPS J. 2006;8:298–306. doi: 10.1007/BF02854900. PubMed DOI PMC

Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007;14:1347–1356. doi: 10.1016/j.chembiol.2007.11.006. PubMed DOI PMC

Morales P., Hurst D.P., Reggio P.H. Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog. Chem. Org. Nat. Prod. 2017;103:103–131. PubMed PMC